Alongside diabetes, Novo Nordisk 'poised for top spot in hemophilia'
This article was originally published in Scrip
Executive Summary
Not satisfied by being world's top diabetes company, Novo Nordisk is set to become the market leader in hemophilia as it builds on its leadership position in the factor VIIa segment and branches out with new offerings for hemophilia A and hemophilia B. This is the conclusion of a new report published by Datamonitor Healthcare entitled Key Companies in Hemophilia.